The manufacturer of a breast cancer drug that offers a last hope to patients could have been "more flexible" to help make the drug affordable for the NHS, a health service boss said.
Sir Andrew Dillon, chief executive of the NHS financial watchdog Nice, which has ruled Kadcyla is too expensive for NHS use, said:
Although Roche proposed a discount to the full list price of Kadcyla, it made little difference to its value for money, leaving it well above the top of our specially extended range of cost effectiveness for cancer drugs.
We are really disappointed that Roche were not able to demonstrate more flexibility to help us make a positive recommendation. The company is well aware that we could not have recommend Kadcyla at the price it proposed.
More top news
A major error in paying disability and sickness benefits to 75,000 people is to be put right - at a potential cost of up to £500 million.
A 24-year-old man suffered a deep cut to his ear after another passenger leaned over and bit it during a row.
Wintry feel to end the week